Fei Liang

机构：American Petroleum Institute, Shandong Provincial Water Resources Research Institute · ORCID：0000-0002-4184-7844

发表论文 244 篇 · 总被引 4460 次 · h-index 35

代表论文

• Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer (2025 · JAMA · 被引 112)
• Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial (2025 · The Lancet · 被引 51)
• Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study (2025 · The Lancet Oncology · 被引 20)
• Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial (2025 · Nature Cancer · 被引 12)
• Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring (2025 · Molecular Cancer · 被引 12)
• Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study (2025 · BMC Medicine · 被引 7)